Market gaps Small scale, on-body subcutaneous drug delivery platform with wearable, discreet solutions presents an opportunity to partner with mid to large pharma seeking patient-friendly administration for injectable therapies and biologics.

Clinical traction Formerly Cam Med, rebranded as Qlibrium with recognition in MassChallenge and MedTech Innovator programs indicating credibility and potential for collaborating on pilot programs and joint development with larger medical device and pharma companies.

Growth potential Revenue stage under one million dollars suggests readiness for strategic partnerships, capital-efficient pilots, and co-development deals with larger manufacturers looking to diversify delivery modalities.

Tech readiness Existing tech stack and cloud-based platform indicate capabilities for secure data integration, remote monitoring, and interoperability with pharma digital health ecosystems—alignment for connected device collaborations.

Competitive positioning Positioned as an innovative, wearable on-body delivery platform with potential to complement established players in the medical device industry, offering a modular solution that can slot into broader product portfolios.